Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Brookstone Capital Management lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,521 shares of the biopharmaceutical company’s stock after purchasing an additional 624 shares during the period. Brookstone Capital Management’s holdings in TG Therapeutics were worth $527,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TGTX. NBC Securities Inc. boosted its position in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the period. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new position in TG Therapeutics during the 3rd quarter worth $53,000. Values First Advisors Inc. bought a new stake in TG Therapeutics during the 3rd quarter valued at approximately $58,000. Finally, GAMMA Investing LLC increased its position in TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Up 1.4 %

Shares of NASDAQ:TGTX opened at $29.55 on Friday. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84. The firm has a market cap of $4.60 billion, a P/E ratio of -295.47 and a beta of 2.24. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company’s 50-day moving average price is $31.73 and its two-hundred day moving average price is $25.74.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 EPS. As a group, research analysts forecast that TG Therapeutics, Inc. will post 0.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $40.67.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,358 shares of company stock worth $781,497 in the last quarter. 10.50% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.